AVEO Pharmaceuticals Stock Price, News & Analysis (NASDAQ:AVEO)

$3.11 0.05 (1.63 %)
(As of 11/18/2017 01:49 AM ET)
Previous Close$3.11
Today's Range$3.15 - $2.99
52-Week Range$0.50 - $4.24
Volume1.83 million shs
Average Volume3.19 million shs
Market Capitalization$362.02 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17

About AVEO Pharmaceuticals (NASDAQ:AVEO)

AVEO Pharmaceuticals logoAVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:AVEO
  • CUSIP: 05358810
  • Web: www.aveooncology.com
Debt:
  • Debt-to-Equity Ratio: -0.32%
  • Current Ratio: 2.33%
  • Quick Ratio: 2.33%
Sales & Book Value:
  • Annual Sales: $2.52 million
  • Price / Sales: 146.02
  • Book Value: ($0.38) per share
  • Price / Book: -8.18
Profitability:
  • Trailing EPS: ($0.71)
  • Net Income: ($26,880,000.00)
  • Net Margins: -972.31%
  • Return on Equity: -836.92%
  • Return on Assets: -80.17%
Misc:
  • Employees: 20
  • Outstanding Shares: 118,320,000
 

Frequently Asked Questions for AVEO Pharmaceuticals (NASDAQ:AVEO)

What is AVEO Pharmaceuticals' stock symbol?

AVEO Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVEO."

How were AVEO Pharmaceuticals' earnings last quarter?

AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) released its quarterly earnings results on Thursday, May, 4th. The biopharmaceutical company reported ($0.12) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.12) by $0.00. The biopharmaceutical company earned $2.53 million during the quarter. AVEO Pharmaceuticals had a negative return on equity of 836.92% and a negative net margin of 972.31%. View AVEO Pharmaceuticals' Earnings History.

Where is AVEO Pharmaceuticals' stock going? Where will AVEO Pharmaceuticals' stock price be in 2017?

4 brokers have issued 12-month price objectives for AVEO Pharmaceuticals' shares. Their forecasts range from $3.00 to $5.00. On average, they expect AVEO Pharmaceuticals' stock price to reach $4.17 in the next year. View Analyst Ratings for AVEO Pharmaceuticals.

Who are some of AVEO Pharmaceuticals' key competitors?

Who are AVEO Pharmaceuticals' key executives?

AVEO Pharmaceuticals' management team includes the folowing people:

  • Michael P. Bailey, President, Chief Executive Officer, Director (Age 49)
  • Matthew Dallas, Chief Financial Officer (Age 41)
  • Michael N. Needle M.D., Chief Medical Officer (Age 55)
  • Henri A. Termeer, Lead Out Side Director (Age 71)
  • Kenneth M. Bate, Independent Director (Age 66)
  • Anthony B. Evnin Ph.D., Independent Director (Age 76)
  • Robert C. Young M.D., Independent Director (Age 75)

Who owns AVEO Pharmaceuticals stock?

AVEO Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (2.89%), Sphera Funds Management LTD. (1.18%), EAM Investors LLC (0.66%), Point72 Asset Management L.P. (0.25%), Essex Investment Management Co. LLC (0.13%) and OxFORD Asset Management LLP (0.05%). View Institutional Ownership Trends for AVEO Pharmaceuticals.

Who sold AVEO Pharmaceuticals stock? Who is selling AVEO Pharmaceuticals stock?

AVEO Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Perceptive Advisors LLC, Sphera Funds Management LTD. and EAM Investors LLC. View Insider Buying and Selling for AVEO Pharmaceuticals.

Who bought AVEO Pharmaceuticals stock? Who is buying AVEO Pharmaceuticals stock?

AVEO Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, OxFORD Asset Management LLP, Rehmann Capital Advisory Group and Victory Capital Management Inc.. View Insider Buying and Selling for AVEO Pharmaceuticals.

How do I buy AVEO Pharmaceuticals stock?

Shares of AVEO Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AVEO Pharmaceuticals' stock price today?

One share of AVEO Pharmaceuticals stock can currently be purchased for approximately $3.11.

How big of a company is AVEO Pharmaceuticals?

AVEO Pharmaceuticals has a market capitalization of $362.02 million and generates $2.52 million in revenue each year. The biopharmaceutical company earns ($26,880,000.00) in net income (profit) each year or ($0.71) on an earnings per share basis. AVEO Pharmaceuticals employs 20 workers across the globe.

How can I contact AVEO Pharmaceuticals?

AVEO Pharmaceuticals' mailing address is One Broadway, 14Th Floor, CAMBRIDGE, MA 02142, United States. The biopharmaceutical company can be reached via phone at +1-617-5312130 or via email at [email protected]


MarketBeat Community Rating for AVEO Pharmaceuticals (NASDAQ AVEO)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  195 (Vote Outperform)
Underperform Votes:  186 (Vote Underperform)
Total Votes:  381
MarketBeat's community ratings are surveys of what our community members think about AVEO Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for AVEO Pharmaceuticals (NASDAQ:AVEO)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 4 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.17 (33.98% upside)

Consensus Price Target History for AVEO Pharmaceuticals (NASDAQ:AVEO)

Price Target History for AVEO Pharmaceuticals (NASDAQ:AVEO)

Analysts' Ratings History for AVEO Pharmaceuticals (NASDAQ:AVEO)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017B. RileyInitiated CoverageBuy -> Buy$5.00N/AView Rating Details
10/6/2017Seaport Global SecuritiesReiterated RatingBuyN/AView Rating Details
8/28/2017Piper Jaffray CompaniesBoost Price TargetOverweight$3.80 -> $4.50HighView Rating Details
7/13/2017FBR & CoReiterated RatingOutperform$3.00HighView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for AVEO Pharmaceuticals (NASDAQ:AVEO)

Earnings by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

Earnings History by Quarter for AVEO Pharmaceuticals (NASDAQ AVEO)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/4/2017Q1 2017($0.12)($0.12)$2.53 millionViewN/AView Earnings Details
11/4/2016Q3 2016($0.12)($0.07)$0.99 millionViewN/AView Earnings Details
5/10/2016Q1($0.12)($0.13)$1.00 million$1.20 millionViewN/AView Earnings Details
3/15/2016Q415($0.04)($0.11)$3.60 millionViewN/AView Earnings Details
11/9/2015Q315($0.09)$0.14$15.16 millionViewN/AView Earnings Details
8/10/2015Q2($0.16)($0.10)$0.13 millionViewListenView Earnings Details
5/7/2015Q115($0.27)($0.21)$0.13 millionViewN/AView Earnings Details
3/6/2015Q314($0.28)($0.27)$0.12 millionViewListenView Earnings Details
11/5/2014Q3 2014($0.27)($0.28)$0.33 million$0.87 millionViewN/AView Earnings Details
8/11/2014Q214($0.38)($0.35)$0.35 million$1.85 millionViewN/AView Earnings Details
5/7/2014Q1 2014($0.33)($0.12)$0.38 million$15.29 millionViewN/AView Earnings Details
3/13/2014Q413($0.33)($0.32)$0.14 million$0.32 millionViewListenView Earnings Details
11/4/2013Q313($0.47)($0.47)$0.23 million$0.32 millionViewN/AView Earnings Details
8/1/2013Q213($0.56)($0.62)$4.30 million$0.32 millionViewN/AView Earnings Details
4/29/2013Q1 2013($0.72)($0.69)$2.52 million$0.32 millionViewListenView Earnings Details
2/13/2013Q4 2012($0.77)($0.49)$14.49 million$15.53 millionViewN/AView Earnings Details
10/30/2012Q312($0.87)($0.69)$6.57 million$1.02 millionViewN/AView Earnings Details
8/2/2012($0.82)($0.68)ViewN/AView Earnings Details
5/3/2012($0.78)($0.77)ViewN/AView Earnings Details
2/14/2012($0.64)($0.58)ViewN/AView Earnings Details
11/2/2011($0.46)($0.55)ViewN/AView Earnings Details
7/28/2011($0.80)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)
2017 EPS Consensus Estimate: ($0.46)
2018 EPS Consensus Estimate: ($0.24)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.13)($0.13)($0.13)
Q2 20171($0.10)($0.10)($0.10)
Q3 20171($0.17)($0.17)($0.17)
Q4 20173($0.15)$0.02($0.06)
Q1 20181($0.06)($0.06)($0.06)
Q2 20181($0.06)($0.06)($0.06)
Q3 20181($0.06)($0.06)($0.06)
Q4 20181($0.06)($0.06)($0.06)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for AVEO Pharmaceuticals (NASDAQ:AVEO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for AVEO Pharmaceuticals (NASDAQ AVEO)

Insider Ownership Percentage: 4.70%
Institutional Ownership Percentage: 53.94%
Insider Trades by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)
Institutional Ownership by Quarter for AVEO Pharmaceuticals (NASDAQ:AVEO)

Insider Trades by Quarter for AVEO Pharmaceuticals (NASDAQ AVEO)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/28/2017Equity Opportunities Iv GrowthMajor ShareholderBuy6,000,000$0.50$3,000,000.00View SEC Filing  
1/16/2015Matthew D DallasVPSell3,075$0.82$2,521.50View SEC Filing  
1/7/2015Michael P BaileyCEOSell4,484$0.80$3,587.20View SEC Filing  
1/30/2014Joseph VittiglioSVPSell5,430$1.64$8,905.20View SEC Filing  
3/14/2013David Brannon JohnstonCFOSell1,061$7.34$7,787.74View SEC Filing  
3/7/2013Henri A TermeerDirectorBuy55,499$6.73$373,508.27View SEC Filing  
12/13/2012Ngoc Tuan HaCEOBuy75,000$6.65$498,750.00View SEC Filing  
12/13/2012Robert C YoungDirectorBuy2,371$6.78$16,075.38View SEC Filing  
12/3/2012Robert C YoungDirectorBuy1,250$6.41$8,012.50View SEC Filing  
9/13/2012David Brannon JohnstonCFOSell1,386$10.60$14,691.60View SEC Filing  
8/8/2012Robert C YoungDirectorBuy1,000$8.63$8,630.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for AVEO Pharmaceuticals (NASDAQ AVEO)

Source:
DateHeadline
Cancer Space Update: Label Expansion for Three Major DrugsCancer Space Update: Label Expansion for Three Major Drugs
finance.yahoo.com - November 17 at 3:56 PM
What’s Installed For AVEO Pharmaceuticals Inc (AVEO)?What’s Installed For AVEO Pharmaceuticals Inc (AVEO)?
finance.yahoo.com - November 17 at 3:56 PM
EUSA Pharma and AVEO Oncology Announce the First Commercial Launch of FOTIVDA® (tivozanib)EUSA Pharma and AVEO Oncology Announce the First Commercial Launch of FOTIVDA® (tivozanib)
finance.yahoo.com - November 16 at 11:39 AM
Brokers Offer Predictions for AVEO Pharmaceuticals, Inc.s FY2017 Earnings (AVEO)Brokers Offer Predictions for AVEO Pharmaceuticals, Inc.'s FY2017 Earnings (AVEO)
www.americanbankingnews.com - November 15 at 7:32 AM
AVEO Pharmaceuticals (AVEO) vs. Its Competitors Head-To-Head SurveyAVEO Pharmaceuticals (AVEO) vs. Its Competitors Head-To-Head Survey
www.americanbankingnews.com - November 12 at 3:10 AM
FY2017 Earnings Estimate for AVEO Pharmaceuticals, Inc. Issued By Seaport Global Securities (AVEO)FY2017 Earnings Estimate for AVEO Pharmaceuticals, Inc. Issued By Seaport Global Securities (AVEO)
www.americanbankingnews.com - November 10 at 8:34 AM
Pro-Trader Daily: Corporate News Blog - AVEO and EUSA Pharma Report Positive Results for TiNivo Study of Tivozanib and NivolumabPro-Trader Daily: Corporate News Blog - AVEO and EUSA Pharma Report Positive Results for TiNivo Study of Tivozanib and Nivolumab
www.finanznachrichten.de - November 9 at 4:34 AM
AVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda - NasdaqAVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda - Nasdaq
www.nasdaq.com - November 8 at 6:32 PM
Corporate News Blog - AVEO and EUSA Pharma Report Positive Results for TiNivo Study of Tivozanib and NivolumabCorporate News Blog - AVEO and EUSA Pharma Report Positive Results for TiNivo Study of Tivozanib and Nivolumab
finance.yahoo.com - November 8 at 6:32 PM
AVEO Pharmaceuticals Q3 Loss Narrows, Focus on FotivdaAVEO Pharmaceuticals Q3 Loss Narrows, Focus on Fotivda
finance.yahoo.com - November 8 at 6:32 PM
Why AVEO Pharmaceuticals, Inc. Tanked 18.6% in October - Motley FoolWhy AVEO Pharmaceuticals, Inc. Tanked 18.6% in October - Motley Fool
www.fool.com - November 8 at 4:22 AM
Your Daily Pharma Scoop: Anxious Time For Dynavax Longs, VBL Therapeutics Gets A Boost, Roche Gets 2 FDA ApprovalsYour Daily Pharma Scoop: Anxious Time For Dynavax Longs, VBL Therapeutics Gets A Boost, Roche Gets 2 FDA Approvals
seekingalpha.com - November 7 at 6:17 PM
Why AVEO Pharmaceuticals, Inc. Tanked 18.6% in OctoberWhy AVEO Pharmaceuticals, Inc. Tanked 18.6% in October
finance.yahoo.com - November 7 at 6:17 PM
AVEO Reports Third Quarter 2017 Financial Results and Provides Business UpdateAVEO Reports Third Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - November 7 at 6:17 PM
AVEO reports 3Q lossAVEO reports 3Q loss
finance.yahoo.com - November 7 at 6:17 PM
Company Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Provides 3Q:17 UpdateCompany Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Provides 3Q:17 Update
finance.yahoo.com - November 7 at 6:17 PM
31 Stocks Moving In Mondays Mid-Day Session31 Stocks Moving In Monday's Mid-Day Session
www.benzinga.com - November 6 at 5:11 PM
AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell CarcinomaAVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma
finance.yahoo.com - November 6 at 5:11 PM
AVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell CarcinomaAVEO Oncology and EUSA Pharma Announce Promising Phase 1 Results from the Phase 1/2 TiNivo Study of Tivozanib and Nivolumab in Renal Cell Carcinoma
finance.yahoo.com - November 6 at 5:11 PM
AVEO Pharmaceuticals, Inc.’s (AVEO) and EUSA Pharma’s Tivozanib Combo Demonstrates Promise as a Potential Treatment for Advanced Renal Cell CarcinomaAVEO Pharmaceuticals, Inc.’s (AVEO) and EUSA Pharma’s Tivozanib Combo Demonstrates Promise as a Potential Treatment for Advanced Renal Cell Carcinoma
finance.yahoo.com - November 6 at 5:11 PM
AVEO Pharmaceuticals, Inc.’s (AVEO) and EUSA Pharma’s Tivozanib Combo Demonstrates Promise as a Potential Treatment for Advanced Renal Cell CarcinomaAVEO Pharmaceuticals, Inc.’s (AVEO) and EUSA Pharma’s Tivozanib Combo Demonstrates Promise as a Potential Treatment for Advanced Renal Cell Carcinoma
finance.yahoo.com - November 6 at 5:11 PM
AVEO Pharmaceuticals: Buy The Dip - Seeking AlphaAVEO Pharmaceuticals: Buy The Dip - Seeking Alpha
seekingalpha.com - November 3 at 4:37 PM
Is AVEO Pharmaceuticals Poised for a Beat in Q3 Earnings?Is AVEO Pharmaceuticals Poised for a Beat in Q3 Earnings?
finance.yahoo.com - October 31 at 5:22 PM
Is AVEO Pharmaceuticals Poised for a Beat in Q3 Earnings?Is AVEO Pharmaceuticals Poised for a Beat in Q3 Earnings?
finance.yahoo.com - October 31 at 5:22 PM
AVEO Pharmaceuticals, Inc. (AVEO) Given Average Recommendation of "Buy" by AnalystsAVEO Pharmaceuticals, Inc. (AVEO) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - October 31 at 1:34 AM
AVEO Pharma Will EU Acceptance of FOTIVDA Influence FDA, Pipeline ReviewAVEO Pharma Will EU Acceptance of FOTIVDA Influence FDA, Pipeline Review
finance.yahoo.com - October 30 at 5:13 PM
ETFs with exposure to AVEO Pharmaceuticals, Inc. : October 30, 2017ETFs with exposure to AVEO Pharmaceuticals, Inc. : October 30, 2017
finance.yahoo.com - October 30 at 5:13 PM
AVEO Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AVEO) : October 18, 2017AVEO Pharmaceuticals, Inc. – Value Analysis (NASDAQ:AVEO) : October 18, 2017
finance.yahoo.com - October 18 at 5:28 PM
AVEO Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AVEO-US : October 17, 2017AVEO Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : AVEO-US : October 17, 2017
finance.yahoo.com - October 17 at 5:04 PM
Here's Why AVEO Pharmaceuticals Dropped as Much as 16.3% TodayHere's Why AVEO Pharmaceuticals Dropped as Much as 16.3% Today
finance.yahoo.com - October 17 at 5:04 PM
Heres Why AVEO Pharmaceuticals Dropped as Much as 16.3% TodayHere's Why AVEO Pharmaceuticals Dropped as Much as 16.3% Today
www.fool.com - October 17 at 4:17 PM
AVEO Oncology Announces Phase 1 Results from TiNivo Study to be Presented at the 16th International Kidney Cancer SymposiumAVEO Oncology Announces Phase 1 Results from TiNivo Study to be Presented at the 16th International Kidney Cancer Symposium
finance.yahoo.com - October 16 at 5:01 PM
AVEO Pharmaceuticals - So, About That Death Rattle - Seeking AlphaAVEO Pharmaceuticals - So, About That Death Rattle - Seeking Alpha
seekingalpha.com - October 13 at 4:51 PM
AVEO Pharmaceuticals, Inc. (AVEO) Short Interest UpdateAVEO Pharmaceuticals, Inc. (AVEO) Short Interest Update
www.americanbankingnews.com - October 13 at 1:32 AM
Featured Company News - AVEO Declares Completion of TIVO-3 Study Futility AnalysisFeatured Company News - AVEO Declares Completion of TIVO-3 Study Futility Analysis
finance.yahoo.com - October 9 at 5:09 PM
Seaport Global Securities Begins Coverage on AVEO Pharmaceuticals, Inc. (AVEO)Seaport Global Securities Begins Coverage on AVEO Pharmaceuticals, Inc. (AVEO)
www.americanbankingnews.com - October 7 at 2:58 PM
 Analysts Expect AVEO Pharmaceuticals, Inc. (AVEO) to Announce -$0.05 EPS Analysts Expect AVEO Pharmaceuticals, Inc. (AVEO) to Announce -$0.05 EPS
www.americanbankingnews.com - October 7 at 12:14 PM
AVEO Pharmaceuticals, Inc. (AVEO) Given Consensus Recommendation of "Buy" by AnalystsAVEO Pharmaceuticals, Inc. (AVEO) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - October 6 at 9:02 AM
BRIEF-Aveo Pharmaceuticals- Tivo-3 study will continue as planned without modificationBRIEF-Aveo Pharmaceuticals- Tivo-3 study will continue as planned without modification
www.reuters.com - October 5 at 7:12 PM
AVEO Oncology Announces Completion of TIVO-3 Study Futility Analysis with No Changes to Study ProtocolAVEO Oncology Announces Completion of TIVO-3 Study Futility Analysis with No Changes to Study Protocol
finance.yahoo.com - October 5 at 7:12 PM
AVEO Oct 2017 1.000 callAVEO Oct 2017 1.000 call
finance.yahoo.com - October 5 at 2:08 PM
Harry Boxer’s four stocks that are breaking out this weekHarry Boxer’s four stocks that are breaking out this week
finance.yahoo.com - October 5 at 2:08 PM
Two Techs And Two Biotechs Breaking OutTwo Techs And Two Biotechs Breaking Out
finance.yahoo.com - October 5 at 2:08 PM
Biotech Stocks on Investors Radar -- Athersys, AVEO Pharma, BioDelivery Sciences, and BioLine Rx - PR Newswire (press release)Biotech Stocks on Investors' Radar -- Athersys, AVEO Pharma, BioDelivery Sciences, and BioLine Rx - PR Newswire (press release)
www.prnewswire.com - October 4 at 1:52 PM
ETFs with exposure to AVEO Pharmaceuticals, Inc. : September 26, 2017ETFs with exposure to AVEO Pharmaceuticals, Inc. : September 26, 2017
finance.yahoo.com - October 2 at 4:05 PM
AVEO Pharmaceuticals (AVEO) Presents At Cantor Fitzgerald Global Healthcare Conference - SlideshowAVEO Pharmaceuticals (AVEO) Presents At Cantor Fitzgerald Global Healthcare Conference - Slideshow
seekingalpha.com - September 28 at 4:36 PM
Financial Contrast: BioCryst Pharmaceuticals (BCRX) & AVEO Pharmaceuticals (AVEO)Financial Contrast: BioCryst Pharmaceuticals (BCRX) & AVEO Pharmaceuticals (AVEO)
www.americanbankingnews.com - September 27 at 4:32 PM
AVEO Flat on New Study with EUSAAVEO Flat on New Study with EUSA
www.baystreet.ca - September 20 at 4:59 PM
BRIEF-AVEO Oncology and EUSA Pharma announce TiNivo combination study opt-inBRIEF-AVEO Oncology and EUSA Pharma announce TiNivo combination study opt-in
www.reuters.com - September 20 at 4:59 PM
AVEO Oncology and EUSA Pharma Announce TiNivo Combination Study Opt-inAVEO Oncology and EUSA Pharma Announce TiNivo Combination Study Opt-in
finance.yahoo.com - September 20 at 4:59 PM

Social Media

Financials

Chart

AVEO Pharmaceuticals (NASDAQ AVEO) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.